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The developmentally important hedgehog (Hh) pathway is activated by binding of Hh to patched (Ptch1), releasing
smoothened (Smo) and the downstream transcription factor glioma associated (Gli) from inhibition. The mechanism
behind Ptch1-dependent Smo inhibition remains unresolved. We now show that by mixing Ptch1-transfected and
Ptch1 small interfering RNA–transfected cells with Gli reporter cells, Ptch1 is capable of non–cell autonomous
repression of Smo. The magnitude of this non–cell autonomous repression of Smo activity was comparable to the
fusion of Ptch1-transfected cell lines and Gli reporter cell lines, suggesting that it is the predominant mode of action.
CHOD-PAP analysis of medium conditioned by Ptch1-transfected cells showed an elevated 3b-hydroxysteroid content,
which we hypothesized to mediate the Smo inhibition. Indeed, the inhibition of 3b-hydroxysteroid synthesis impaired
Ptch1 action on Smo, whereas adding the 3b-hydroxysteroid (pro-)vitamin D3 to the medium effectively inhibited Gli
activity. Vitamin D3 bound to Smo with high affinity in a cyclopamine-sensitive manner. Treating zebrafish embryos
with vitamin D3 mimicked the smo
–/– phenotype, confirming the inhibitory action in vivo. Hh activates its signalling
cascade by inhibiting Ptch1-dependent secretion of the 3b-hydroxysteroid (pro-)vitamin D3. This action not only
explains the seemingly contradictory cause of Smith-Lemli-Opitz syndrome (SLOS), but also establishes Hh as a unique
morphogen, because binding of Hh on one cell is capable of activating Hh-dependent signalling cascades on other
cells.
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Introduction
Signal transduction of the morphogen hedgehog (Hh) is
highly unusual, with many features unique to this signalling
system, many of which are only partly understood [1]. For
instance, Hh signalling is mediated by two membrane
proteins: patched (Ptch1) and smoothened (Smo). The former
is a 12-pass transmembrane protein [2,3] resembling the
Niemann-Pick disease type C1 (NPC1) protein (which is
involved in cholesterol trafﬁcking and has a pump function);
the latter is a seven-pass transmembrane protein that
resembles a G protein–coupled receptor [4]. In the absence
of the inhibitory receptor Ptch1 (or in the case of a speciﬁc
mutation rendering Ptch1 dysfunctional), Smo is constitu-
tively active and leads to the activation and nuclear trans-
location of its downstream transcription factor glioma
associated (Gli). Under normal physiological circumstances,
the activation of the signalling pathway is caused by binding
of Hh to Ptch1, resulting in the internalisation of Ptch1 and,
consequently, the alleviation of the inhibitory effect of Ptch1
on Smo [5,6]. The exact mechanism behind Ptch1 inhibition
of Smo, however, remains unclear [7].
Similarities in the phenotypes of humans with inherited
disorders of sterol biosynthesis (Figure 1A, lathosterolosis and
Smith-Lemli-Opitz syndrome [SLOS]) and the phenotypes
seen with mutations in the Hh signalling pathway have led to
the suggestion that cholesterol-synthesizing enzymes may
somehow be involved in Ptch1-dependent Smo inhibition [1].
Sterol content has been found to be crucial to a cell’s
responsiveness to Hh, independent of proper Hh sterolation
[8], suggesting that sterol—or more speciﬁcally cholesterol—
levels are pivotal to a cell’s ability to respond to Hh, rather
than to the accumulation of a speciﬁc inhibitory metabolite.
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PLoS BIOLOGYFigure 1B depicts the proposed possible modes of Ptch1
action on Smo. Because Ptch1 and Smo do not unambigu-
ously show physical association and because Ptch1 can inhibit
Smo substoichiometrically, direct binding of Ptch1 to Smo as
shown in Figures 1B, columns 1 and 2, seems an unlikely
mechanism of inhibition [9]. Ptch1 shares high homology (for
instance, a sterol-sensing domain) with NPC1, a protein
involved in cholesterol trafﬁcking [10], as well as with various
(prokaryotic) pump proteins. Also, several small molecules
with homology to cholesterol that act as Hh pathway
antagonists have been identiﬁed [11–13]. Cyclopamine, a
well-known antagonist of Smo, has been widely used for
assessing the effects of Hh pathway inhibition in several
model systems (for example, in [14]). Consequently, it has
been anticipated that in the absence of Hh, Ptch1 translocates
a small molecule resembling cholesterol across the mem-
brane, acting as a Smo antagonist. This hypothesis is
summarized in Figure 1B, column 3.
A consequence of the proposed ‘‘pump’’ model for Ptch1 is
that the action of Ptch1 should be non–cell autonomous. We
set out to test this prediction, and we established that Hh
activates its signalling cascade by inhibiting Ptch1-dependent
secretion of the 3b-hydroxysteroid (pro-)vitamin D3. These
data provide fundamental new insight into the molecular
mechanisms by which Hh exerts its action in pathophysiology.
Results
A Model System for Measuring Ptch1-Dependent Smo
Inhibition
An experimental system allowing the study of intercellular
inhibitory actions of Ptch1 on Smo should fulﬁll four
requirements: (1) cells must be capable of sustaining Ptch1
expression, (2) expressed Ptch1 must be functionally active,
(3) the inhibition of Gli activity should be Smo-mediated, and
(4) endogenous Hh should not be a contributing factor. To set
up a model system for studying Ptch1-dependent inhibition,
C3H/10T1/2 ﬁbroblasts, which are cells extensively used for
Hh research, were transfected with an 83 Gli–binding site
luciferase construct [15] together with Ptch1, Smo, Smo and
Ptch1, or Gli1.
Overexpression of Ptch1 drove cells into apoptosis
(unpublished data, consistent with [16]), possibly a reﬂection
of the function of Ptch1 as a so-called dependence receptor.
To overcome this problem, we performed experiments in the
presence of 20 lM caspase inhibitor zVADfmk. Under these
conditions, transfection with a Ptch1 expression construct led
to efﬁcient overexpression of Ptch1 as detected by Western
blot (Figure 2A). Transfection of Ptch1 effectively inhibited
transactivation of the Gli reporter in the presence of
overexpressed Smo (Figure 2B). The Ptch1-insensitive mutant
SmoM2 [11,17] was not inhibited by Ptch1 cotransfection and
showed a high basal Gli activity. Ptch1 transfection in the
absence of Smo overexpression yielded no inhibition below
control values, which has been described previously [18]. This
ﬁnding suggests the presence of high basal Ptch1 levels and
indicates the speciﬁcity of Ptch1 inhibition acting through
Smo in our system. The inhibitory effect of the high basal
Ptch1 levels could be overcome by the addition of 1 lg/ml
recombinant N-terminal Sonic hedgehog (Shh) for 6 h, as can
be seen from the high reporter activity upon stimulation
(Figure 2B). Addition of 1 lg/ml 5E1 Shh-blocking antibody
[19] could counteract the stimulation by Shh. Because Smo
and Gli overexpression were capable of increasing trans-
activation of the Gli reporter despite the presence of a
caspase inhibitor, our experimental system is a valid readout
for Smo-mediated Gli activity.
The requirement for Smo overexpression to respond to
Ptch1 inhibition and the high responsiveness to exogenously
added Shh suggest that endogenous Hh production is not a
major factor in our setup, although others have shown mRNA
for Indian hedgehog (Ihh) and Shh in C3H/10T1/2 cells
[20,21]. To exclude Hh protein excretion by our C3H/10T1/2
cells as a contributing factor in our model system, we
performed Western blot analysis on Shh-spiked medium
and medium from ﬁbroblast cell culture. The cells did not
excrete Hh protein (Figure 2C). As can be seen, the detection
limit was about 5 ng/ml, which was not reached in the (43
concentrated) medium, indicating that the Hh concentration
in the medium was less than 1.25 ng/ml, a concentration too
low to evoke a response [22]. Reprobing the blot for Ihh did
not yield a signal for the medium either.
Figure 1. Cholesterol Synthesis and Possible Modes of Action of Ptch1
(A) Shown is a schematic representation of cholesterol synthesis. Boxed
are lathosterol and 7-DHC, cholesterol precursors known to accumulate
in lathosterolosis and SLOS patients, respectively. Mutations in or genetic
loss of sterol C5-desaturase (Sc5d) cause stacking of lathosterol, whereas
dysfunction of 7-DHC reductase (Dchr7) or the addition of its synthetic
inhibitor AY-9944 causes accumulation of 7-DHC. The conversion of 7-
DHC to vitamin D3 (cholecalciferol) is mediated by UV light. Statins, like
pravastatin, inhibit HMG-CoA red u c t a s e ,t h ee n z y m et h a tf o r m s
mevalonate.
(B) Shown are three possible models for the inhibitory action of the Hh
receptor Ptch1 on Smo. (1) A cell-autonomous mode of action, in which
direct binding of Ptch1 inhibits Smo. (2) An intracellular inhibitory action,
mediated by direct binding of Ptch1 to Smo. (3) The model in which
Ptch1 pumps an inhibitory small molecule that is capable of Smo-
repression intercellularly (as well as intracellularly; not shown).
DOI: 10.1371/journal.pbio.0040232.g001
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Repression of Smoothened by PatchedPtch1 Can Inhibit Smo in a Non–Cell Autonomous Fashion
To assess the ability of Ptch1 to act upon Smo on another
cell, we used a ‘‘mix-and-match’’ approach (as schematically
shown in Figure 3A), in which two populations of cells are
mixed. The donor population expresses Ptch1 at different
levels (using an overexpression construct or small interfering
RNA [siRNA]) that could act on reporter cells with a
constitutively active Hh pathway (reporter cells: Smo recep-
tor overexpressed and a Gli-luciferase reporter). We mixed
reporter cells with vector, Ptch1, Ptch1 siRNA and scrambled
control siRNA transfectants. Cell populations were detached
by EDTA treatment, mixed, and replated. By using two
ﬂuorescent tracers for labelling the cell populations, the
capability of this procedure to obtain a homogenous mixture
could be assessed. Figure 3A shows that combining two cell
populations yields evenly mixed cells with intimate cell-cell
contacts (micrograph). When Gli reporter cells were mixed
with Ptch1- overexpressing cells in these mix-and-match
experiments, a signiﬁcant reduction in Smo-mediated Gli
activation could be seen compared with control. This
inhibition could not be diminished by addition of 1 lg/ml
5E1 Hh-blocking antibody (Figure 3A), again demonstrating
that endogenous Hh is not a contributing factor in our
experimental setup. This is important, speciﬁcally because
the presence of Hh in the medium would increase reporter
activity. As Ptch1 scavenges Hh from the medium, medium of
Ptch1-overexpressing cells would contain lower Hh levels
than would control or Ptch1 siRNA-transfected cells. The
reduction in reporter activity as consequence of such
scavenging would mask the action of a potential inhibitory
molecule. The addition of 1 lg/ml recombinant Shh, which
should inhibit Ptch1 present in these experiments, was able to
abolish the inhibition conferred by Ptch1. Mixing reporter
cells with Ptch1 siRNA-transfected cells increased Smo-
dependent reporter activity (Figure 3A, blue bars), demon-
strating that the inhibition is Ptch1 dependent and again
suggests that C3H/10T1/2 cells have a signiﬁcant basal level of
Ptch1 activity. Showing opposite effects of Ptch1 siRNA
versus DNA excludes any overexpression artefacts from
responsibility for the observed non–cell autonomous effect.
To exclude cell-speciﬁc artefacts, the procedures were also
performed with MDA-MB-231 breast tumour cells, which had
even higher levels of endogenous PTCH1 and SMO than the
C3H/10T1/2 ﬁbroblasts (Western blot, unpublished data).
Indeed, using these cells yielded similar but more pro-
nounced effects, as did the C3H/10T1/2 cells (Figure 3A,
hatched bars).
To determine the maximal inhibition Ptch1 confers in a
cell-autonomous fashion—that is, the extent to which Ptch1
can inhibit Smo on the same cell—we mixed and fused the
two previously described cell populations. PEG1500 induced
efﬁcient cell fusion, which was evident from blended staining
of PEG1500-treated cells and the multinucleated cells
(procedure and micrographs shown in Figure 3B, left panel).
Fusion of reporter cells with Ptch1-overexpressing cells again
showed a reduction in Gli activation, similar to that observed
in the mix-and-match experiments (Figure 3A). The reduc-
tion in reporter activity was of the same magnitude as that
obtained in the mixing experiments. Therefore, we conclude
that Ptch1 inhibition of Gli reporter activity in our system is
mediated mainly intercellularly.
The speciﬁcity of the observed inhibitory action of Ptch1
acting through Smo was assessed by using the Ptch1-
insensitive SmoM2 mutant, as previously shown in Figure
2B. As can be seen in Figure 3C, SmoM2-transfected reporter
cells are no longer sensitive to mixing with Ptch1-over-
Figure 2. Confirmation of Functionality of Constructs and Model System
Used
(A) Transfection of Ptch1 expression construct in C3H/10T1/2 fibroblasts
increased Ptch1 expression over basal expression, as seen on Western
blot. Actin levels remained unaltered; cells were lysed 24 h post
transfection.
(B) C3H/10T1/2 cells are sensitive to Hh pathway components as
indicated by Gli reporter activity when pathway components are
expressed: Smo increased Hh pathway activity as determined by Gli
reporter luciferase assay. Cotransfection of Ptch1 suppressed Smo-
induced Gli activation. Transfection of Ptch1 in the absence of Smo
overexpression did not decrease Gli activity below control levels. Shh
stimulation (1 lg/ml for 6 h, 16 h post transfection) and transfection of a
Gli1 expression construct showed highest reporter activity, as expected.
Addition of 1 lg/ml Shh-blocking antibody 5E1 reduced Shh-mediated
activation of Gli reporter activity. The Ptch1-insensitive mutant SmoM2
showed a high basal activity that could not be diminished by
cotransfecting Ptch1, as expected. Cells were transfected and lysed after
24 h. Values shown are relative light unit (RLU) values corrected for an
internal CMV Renilla standard, expressed as percent increase relative to
vector (pcDNA 3.1–) transfection or control stimulation. Depicted is the
mean 6 SEM. (n ¼ 4; *, p , 0.05; **, p , 0.01).
(C) Shh concentration in medium is below the detection limit (5 ng/ml)
of Western blotting. Medium was spiked with decreasing concentrations
of recombinant Shh, and blotted along with a 43concentrated medium
sample obtained from C3H/10T1/2 fibroblasts (incubated for 16 h at a
volume-to-surface ratio identical to the mix-and-match and medium
transfer experiments).
DOI: 10.1371/journal.pbio.0040232.g002
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Repression of Smoothened by Patchedexpressing donor cells, even when cotransfected with wild-
type Smo. These ﬁndings led us to suggest the model for
Ptch1 action as depicted in Figure 1B, column 3, and Figure
3D, in which Ptch1 on one cell is capable of speciﬁcally
inhibiting Smo on another cell, to act non–cell autonomously.
Non–Cell Autonomous Ptch1-Dependent Smo Inhibition
Is Carried Out by a Medium-Borne Factor
The intercellular Ptch1-mediated inhibition of Smo as
identiﬁed in the mix-and-match experiments may be con-
ferred by either an inhibitory molecule secreted or trans-
Figure 3. Ptch1 Inhibits Smo Intercellularly
(A) Detaching and mixing of two populations of fluorescently labelled cells resulted in a homogenous mixture with intimate cell–cell contacts. The
procedure is summarized in the left panel. Original magnification is 4003. Intercellular capacity of Ptch1 to inhibit Smo was assessed by mixing reporter
cells overexpressing Smo and a Gli reporter with Ptch1-overexpressing donor cells. The observed decrease in Gli reporter activity could not be inhibited
by the addition of 1 lg/ml 5E1 Shh-blocking antibody. Exogenously added Shh (1 lg/ml) was capable of abolishing the Ptch1-mediated inhibition.
Transfecting donor cells with Ptch1 siRNA reversed the inhibitory effect (blue bars). MDA-MB-231 breast carcinoma cells (hatched bars) showed a
response similar to the C3H/10T1/2 fibroblasts’. Donor cells were transfected, washed (16 h post transfection), mixed with reporter cells, and lysed after
6 to 8 h. Shown are RLU values corrected for an internal CMV Renilla luciferase control, expressed as percent differences relative to control-transfected
donor cells (vector DNA or scrambled control siRNA). (n   4; *, p , 0.05; ***, p , 0.005). Depicted is the mean 6 SEM.
(B) Fusion of reporter cells with Ptch1 overexpressing donor cells showed a decrease in Gli reporter activity comparable in magnitude to the inhibition
observed in mixed cells. Right panel: treating fluorescently labelled cells with PEG1500 4 h after mixing resulted in multiple nuclei per cell and
composite cell colours, indicating successful cell fusion. Magnification is 1,0003. Statistics and incubation times are as in (A).
(C) To assess the specificity of Ptch1 acting on Smo, reporter cells expressing the Ptch1-insensitive mutant SmoM2 (as indicated on the y-axis) were
mixed with donor cells. The loss of inhibition indicates the specificity of Ptch1 acting through Smo in the mix-and-match setup. Statistics and incubation
times are as in (A).
(D) Shown is a model for the proposed intercellular action of Ptch1 inhibition following the results obtained in the mix-and-match experiments.
DOI: 10.1371/journal.pbio.0040232.g003
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Repression of Smoothened by Patchedlocated by Ptch1 or by diffusion of a cytosolic mediator
through tight junctions. The latter possibility is less likely,
because it would result in a merged ﬂuorophore signal in the
mixed cell population, which was not observed (Figure 3A).
Indeed, important support for the possibility that Ptch1
secretes a Smo inhibitory molecule into the medium was
obtained from experiments in which medium conditioned on
Ptch1-transfected cells was transferred to reporter cells in
which Gli activity was assayed (procedure schematically
shown in Figure 4A, left panel).
By using this experimental setup, we found that medium
conditioned on Ptch1-transfected cells exerted a strong
inhibitory effect on Gli activation as compared with medium
conditioned on control-transfected cells (Figure 4A). This
inhibition could not be blocked by the addition of 1 lg/ml
Shh or 5E1 to the reporter cells. The inability of Shh to
prevent Ptch1-conditioned, medium-dependent inhibition of
Smo activity is expected, because the transferred medium
does not contain donor cells expressing Ptch1 on which Shh
should exert its action, and the presence of the medium-
borne factor in the Ptch1-conditioned medium shortcuts the
function of endogenous Ptch1 in the reporter cells. Using
MDA-MB-231 cells in this setup, similar results were obtained
(Figure 4A, hatched bars). As for the mix-and-match experi-
ments, medium conditioned on Ptch1 siRNA-transfected cells
increased Smo-dependent reporter activity in both cell lines.
Medium conditioned on mouse embryonic ﬁbroblasts (MEFs)
from Ptch1 knockout mice [23] showed a distinct deﬁciency in
their capacity to inhibit S m oc o m p a r e dw i t hm e d i u m
conditioned on wild-type (Ptch1
þ/þ) MEFs (Figure 4, pink
bars). This inhibitory effect could again not be conferred to
reporter cells transfected with the Ptch1-insensitive SmoM2.
The opposite effects, as observed with Ptch1 DNA trans-
fection versus either Ptch1 siRNA transfection (blue bars) or
genetic Ptch1-deﬁcient MEFs, exclude transfection artefacts
on the donor cells as the potential cause of the observed
effects. Overall, these ﬁndings suggest that Ptch1 transfers a
molecule to the medium that inhibits Smo activity. Medium
conditioned on Ptch1-overexpressing MDA-MD-231 cells
could inhibit Gli activity in C3H/10T1/2 cells and vice versa
(unpublished data), suggesting that the inhibitory factor is
not species-speciﬁc, at least not among mammals.
Using serum-free medium, we could confer no inhibitory
action of Ptch1-conditioned medium on reporter cells
(Figure 4A). Serum-free medium contains no lipoproteins,
which implies an important role for lipoproteins in convey-
ing the inhibitory signal from cell to cell. Alternatively,
serum-free medium also lacks lipids, which could stress the
necessity for lipids supplied in the medium for Hh
responsiveness [8]. However, serum-free conditions for 8 h
(the incubation time in our experiments) do not deplete a
cell’s cholesterol metabolism, arguing in favour of a role for
lipoproteins in communicating the inhibitory signal.
Ptch1-Dependent Secretion of 3b-Hydroxysteroids
The conditioned media were subjected to fast performance
liquid chromatography (FPLC)-coupled cholesterol oxidase
peroxidase-amidopyrine (CHOD-PAP) analysis, a technique
that analyzes 3b-hydroxysteroid content. The Ptch1-condi-
tioned medium was found to be enriched with 3b-hydrox-
ysteroids relative to medium conditioned by control cells
(Figure 4B and 4C; quantiﬁcation of FPLC proﬁles as mM
total 3b-hydroxysteroid). Judging from the retention proﬁle,
these 3b-hydroxysteroids were present on low-density lip-
oprotein (LDL) particles and, to a lesser extent, on very-low-
density lipoprotein (VLDL). High-density lipoprotein (HDL)
3b-hydroxysteroid levels remained constant in all conditions.
Medium incubated on cells transfected with siRNA for Ptch1
was virtually devoid of LDL-associated 3b-hydroxysteroids.
This correlation between modiﬁed Ptch1 levels and the
accumulation of 3b-hydroxysteroid molecules in the medium
suggests that Ptch1 translocates or pumps these 3b-hydrox-
ysteroids into the medium and thereby transfers the Smo
inhibitory activity.
3b-Hydroxysteroids Are Necessary for Ptch1-Dependent
Smo Inhibition
In the presence of pravastatin, a 3-hydroxy-3-methylglu-
taryl coenzyme A (HMG-CoA) reductase inhibitor that
abrogates the biosynthesis of the 3b-hydroxysteroid precur-
sor mevalonate (Figure 1A), LDL-associated 3b-hydroxyste-
roid (named LDL-C on axis) levels were substantially reduced
(Figure 4C), and, correspondingly, reduced Gli inhibition was
observed in Ptch1-overexpressing reporter cells as shown in
Figure 4D. Conversely, the 3b-hydroxysteroid precursor
mevalonate strongly increased LDL-associated 3b-hydroxys-
teroids and Ptch1-mediated inhibition of Gli transactivation.
If the observed effects of steroid synthesis modiﬁers on Gli
activation are Smo-speciﬁc, Hh responses mediated by Ptch1
(but not those by Smo) should remain unaffected. The
endocytosis of Ptch1 is such a Smo-independent response
to Hh [3,4]. By using [3H]-sucrose as a tracer [24], we observed
no effect of 1 mM pravastatin on Hh-mediated endocytosis
(Figure 4E), and thus the effects of steroid-synthesis inhibitors
are Smo-speciﬁc. The above-mentioned reporter data, how-
ever, are not from medium transfer experiments, and the
inhibition or stimulation of cholesterol synthesis and the
concomitant effects on Gli activity do not unequivocally
prove the contribution of sterol biosynthesis to the inter-
cellular action of Ptch1.
Using Dhcr7
–/– and Sc5d
–/– MEFs to Identify the Inhibitory
Compound
The paradoxical phenotype of SLOS patients, in which
diminished Hh signalling is accompanied by an accumulation
of the sterol 7-dehydrocholesterol (7-DHC; see Figure 1A), led
us to hypothesize that 7-DHC might be a Smo inhibitor. To
test this hypothesis, we used MEFs [8] from mice genetically
deﬁcient for 7-DHC reductase (Dhcr7
–/–), because these cells
stack 7-DHC. To conﬁrm the speciﬁcity of 7-DHC as Smo
inhibitor, we also used sterol C5-desaturase (Sc5d
–/–) MEFs
that stack the precursor of 7-DHC (lathosterol) and contain
little or no 7-DHC. Indeed, as shown in Figure 5A, Dhcr7
–/–
MEFs had a signiﬁcantly reduced Gli activity as compared
with Sc5d
–/– MEFs. In addition, the Smo-inhibitory potential
of Dhcr7
–/– MEF-conditioned medium was much higher than
that of Sc5d
–/– MEF-conditioned medium, as shown in the
medium transfer experiment depicted in Figure 5A. In
addition to stacking a speciﬁc metabolite, both MEFs are
equally incapable of sterol synthesis. Our data therefore
argue against reduced sterol levels as being responsible for
the observed Smo inhibition. Overall, these data strongly
suggest that 7-DHC or a Dhcr7-independent metabolite of 7-
DHC have an inhibitory action on Smo.
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Repression of Smoothened by PatchedTo assess whether Ptch1 uses 7-DHC to inhibit Smo, we
performed medium transfer experiments with Ptch1 (or
Ptch1 siRNA)-transfected Dhcr7
–/– and Sc5d
–/– MEFs as donor
cells. If Ptch1 would indeed pump 7-DHC, Ptch1 over-
expression or knockdown in the Sc5d
–/– MEFs should show no
effect on Smo inhibition. As shown in Figure 5B, the Sc5d
–/–
MEFs were severely hampered in their ability to transfer
Ptch1 action to the medium, because neither Ptch1 DNA nor
siRNA transfectants differed from control transfectants in
their ability to inhibit Smo on reporter cells. The Dhcr7
–/–
MEFs, however, were well capable of translating Ptch1
expression levels to differential inhibitory action on reporter
cells. UVB treatment of Dhcr7
–/– MEF-conditioned media,
which catalyzes the reaction from 7-DHC to vitamin D3,
increased the Ptch1 effect on reporter cells, raising the
tantalising option that Ptch1 uses vitamin D3 to inhibit Smo.
Figure 4. Ptch1 Secretes Smo-Inhibitory 3b-Hydroxysteroids
(A) The left panel shows a schematic representation of the medium transfer experiments, in which medium was incubated on (transfected) donor cells
and subsequently transferred to reporter cells. Right panel: intercellular Smo inhibition by Ptch1 is carried by the medium. Medium conditioned by
control-, Ptch1-, or Ptch1 siRNA-transfected (C3H/10T1/2, solid bars, and MDA-MB-231, hatched bars) cells was transferred to Gli reporter cells. The same
inhibitory action for Ptch1 was found as in the mix-and-match experiments. Neither 5E1 blocking antibody nor recombinant Shh addition to the
reporter cells could diminish the inhibitory potential of the conditioned media. Medium conditioned on wild-type (Ptch1
þ/þ) MEFs showed a
pronounced inhibitory effect on reporter cells as compared with Ptch1 knockout (Ptch1
–/–) MEF-conditioned medium. Gli activity in reporter cells
transfected with SmoM2 was not inhibited by Ptch1
þ/þMEF-conditioned medium. In the absence of serum, Ptch1 transfectant conditioned medium did
not contain the inhibitory activity. Incubation times are as in Figure 3B. Values shown are RLU values corrected for an internal CMV Renilla standard and
expressed as percent difference to control-transfected donor cells. Depicted is the mean 6 SEM. (n   4; *, p , 0.05; **, p , 0.01; medium Ptch1-
transfected compared with medium Ptch1 siRNA-transfected).
(B) Vector, Ptch1, and Ptch1 siRNA transfectant-conditioned media investigated with FPLC-coupled CHOD-PAP analysis shows loading of 3b-
hydroxysteroids on lipoproteins by control cells. Medium conditioned by Ptch1-transfected cells shows a strong increase in 3b-hydroxysteroids, mainly
in the LDL fraction. Ptch1 siRNA transfection abolishes 3b-hydroxysteroid loading on LDL. The inset shows the lipid standard FCS containing VLDL, LDL,
and HDL. Medium was incubated on cells for 16 h. Shown are typical profiles.
(C) Shown is quantification of the LDL peaks, expressed as mM. LDL-C shows the Ptch1-induced increase, a reduction by HMG-CoA reductase inhibitor
pravastatin treatment, and the abolition by Ptch1 siRNA transfection of 3b-hydroxysteroid loading on LDL (n ¼ 3; *, p , 0.05; **, p , 0.01).
(D) Pravastatin-inhibited Ptch1 action on Smo-driven Gli reporter activity, whereas the addition of the cholesterol precursor mevalonate enhanced this
inhibition. Cells were transfected, and, after 16 h, pravastatin or mevalonate was added for 6 to 8 h. Depicted is the mean 6 SEM. (n¼4; *, p , 0.05; **,
p , 0.01).
(E) Hh-induced endocytosis is not inhibited by 1 mM pravastatin (n ¼ 24; ***, p , 0.005). Cells were stimulated with 1 lg/ml Shh for 1 h, and
preincubated with 1 mM pravastatin or control for 6 h.
DOI: 10.1371/journal.pbio.0040232.g004
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From the experiments described above, we hypothesized
that the addition of synthetic 7-DHC or vitamin D3 would
inhibit Gli activity in reporter cells as well. Indeed, as can be
seen from Figure 6A, 7-DHC was capable of inhibiting Smo,
but was not nearly as potent as its derivative, vitamin D3. This
ﬁts the observation that UV treatment enhanced the
inhibitory potential of Ptch1-conditioned medium (Figure
5B). The addition of the 7-DHC reductase inhibitor AY-9944
[25] successfully enhanced the effect of vitamin D3 treatment
but was also capable of inhibiting Smo by itself, possibly by
causing accumulation of endogenously synthesized 7-DHC or
by acting as a 7-DHC mimetic. The magnitude of inhibition
conveyed by either the transfer of Ptch1 transfectant–
conditioned medium or Ptch1 cotransfection were both
smaller than that of vitamin D3. In addition, inhibition
conferred by vitamin D3 was stronger than that of 10 lM
cyclopamine. The ﬁnding that AY-9944 was not a necessity
for inhibitory action excludes a role for sterol deprivation in
this model (Figure 1A), because the exogenously added 7-
DHC or vitamin D3 can be readily metabolized by these (wild-
type) ﬁbroblasts to produce downstream sterols.
Shown in Figure 6B is a dose-dependent response of
reporter cells to vitamin D3 for 6 h. In agreement, the level of
inhibitory N-terminal Gli3 protein increased accordingly, as
quantiﬁed from Western blot. This digestion product of Gli3
originates from proteolysis in the SuFu/Fu complex present
in Hh pathway inactive cells and is considered the repressor
form [26]. To exclude cytotoxic artefacts of vitamin D3, we
measured cell viability by MTT reduction. Only at very high (1
mM) concentrations of vitamin D3 could we could observe a
slight decrease in cell viability. Using SmoM2-transfected
reporter cells, Gli reporter inhibition occurred only at 100
lM vitamin D3, and below that concentration, no inhibition
could be observed. This is very similar to the impaired but not
absent response of SmoM2 to cyclopamine [11].
To exclude Gli-independent effects of vitamin D3 from
being responsible for the observed reporter inhibition, we
used a panel of various luciferase reporter constructs. As can
be seen in Figure 6C, interferon-stimulated response element
(pISRE), TATA-like promoter (pTAL), nuclear factor–kappa
B (pNF-jB), and mutant Gli binding site (mGli) luciferase
reporter constructs were not signiﬁcantly inhibited by the
addition of 10 lM vitamin D3 for 6 h, whereas reporter
activity of a TATA-like promoter–luciferase construct was
increased. Thus, the inhibitory effect of vitamin D3 on Gli
reporter activity appears to be a genuine effect of Smo-
dependent signalling.
Figure 6D shows Gli reporter inhibition by vitamin D3 in
the cell lines C3H/10T1/2 and MDA-MB-231 previously used
in the mix-and-match and medium transfer experiments.
Both showed a marked inhibition in reporter activity after
treatment with 10 lMv i t a m i nD 3 .Ptch1
–/– MEFs also
responded to vitamin D3. Because these cells have no Ptch1,
any artefacts of vitamin D3 by interference with Ptch1 action
rather than Smo activity can be excluded.
A consequence of our model in which vitamin D3 or a very
similar molecule mediates Ptch1 action on Smo (Figure 6E) is
that exogenously added vitamin D3 should overrule any effect
of Hh on Ptch1. To conﬁrm this, we stimulated stable Gli-
luciferase transfectants (Shh-LIGHT II) overnight with 10 lM
vitamin D3 and/or 200 ng/ml Shh. What is apparent from
Figure 6F is that in the presence of vitamin D3 reporter
activity could not be increased by the addition of Shh,
conﬁrming our hypothesis.
Scatchard Analysis Reveals Vitamin D3 Binding to Smo
To assess possible binding of vitamin D3 to Smo, we used a
yeast strain (Pichia pastoris) transformed with Smo. The
expression of Smo could be induced by the addition of
methanol to the growth medium (kind gift of Dr. I. Mus-
Veteau [27]). We chose this approach for two reasons: ﬁrst, to
our knowledge there is no vitamin D3 receptor in P. pastoris;
second, baseline (or background) levels of Smo in noninduced
P. pastoris are negligible.
First we conﬁrmed the successful induction of Smo
expression by Western blot using a Smo antibody as shown
in Figure 7A. We then set out to perform a Scatchard analysis
Figure 5. Differentially Modulated Ptch1 Action in Dhcr7
–/– and Sc5d
–/–
MEFs
(A) Basal Gli reporter activity measured in MEFs either deficient for Sc5d
or Dhcr7 shows that the stacking of 7-DHC (in the Dhcr7
–/– MEFs) lowers
Gli activity in the mutant cells compared with lathosterol stacking in the
Sc5d
–/– MEFs. Transfer of the conditioned media to reporter cells
(indicated as ‘‘MEFs as medium donors’’) shows that the inhibitory
potential of the Dhcr7
–/– MEFs is medium-borne. Media were incubated
on donor MEFs for 16 h and transferred to reporter cells for 6 to 8 h. (n  
4; *, p , 0.05; ***, p , 0.005).
(B) Medium transfer of Ptch1, Ptch1 siRNA, or control-transfected Sc5d
–/–
and Dhcr7
–/– MEFs shows that cells stacking lathosterol but lacking 7-
DHC (Sc5d
–/– MEFs) are not able to translate different Ptch1 levels to an
inhibitory action on reporter cells. The Dhcr7
–/– cells were able to
properly convey an inhibitory signal when transfected with Ptch1 or,
inversely, show a diminished inhibitory potential upon Ptch1 siRNA
transfection. UVB treatment of Ptch1 transfectant medium (2 h) amplified
the inhibitory action. Media incubations and statistics are as in (A).
DOI: 10.1371/journal.pbio.0040232.g005
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Repression of Smoothened by Patched[24] with heterologous competition by cyclopamine. Cyclop-
amine is a ligand for Smo, and this enabled us to distinguish
the observed competition from any background by non-
speciﬁc binding or speciﬁc binding to a vitamin D3 receptor
(although it is not known to exist in these cells). As can be
seen from Figure 7B, [3H]-D3 was not capable of speciﬁc
binding to non–methanol induced P. pastoris (BMGY), whereas
after methanol induction (BMMY), speciﬁc binding of [3H]-
D3 was observed that was subject to competition by cyclop-
amine. Cyclopamine replaced [3H]-D3 with an apparent
dissociation constant Kd of 2 nM in this heterologous assay, a
higher afﬁnity than the earlier reported 20-nM afﬁnity of
cyclopamine [28]. Nevertheless, these results show that
vitamin D3 has the potential to bind Smo at the same site
Figure 6. Analysis of Vitamin D3 as a Specific Smo Antagonist
(A) Shown are the Gli reporter inhibitions by 7-DHC, AY-9944, a Dhcr7 inhibitor, vitamin D3, and a combination of the latter two. Also shown is the
inhibition that can be conferred by the well-known Smo antagonist cyclopamine and the previously observed effects for Ptch1 transfectant conditioned
medium as well as Ptch1 cotransfection (data taken from Figure 4B and Figure 2B, respectively). Cells were stimulated with the various compounds for 6
h (16 h past transfection), except for the cotransfection, which was lysed after 24 h (n   4).
(B) A range of concentrations of vitamin D3 was tested for inhibition of Gli reporter activity (also in SmoM2-transfected cells), MTT viability assay, and N-
terminal repressor form Gli3 levels. Cells were stimulated with vitamin D3 for 6 h before lysis. For the reporter assays, RLU values were corrected for an
internal CMV Renilla standard and expressed as percent difference to control stimulated cells (n¼4). The MTT assays shown were raw absorption data
expressed as percent difference to control stimulated (n ¼ 8); MTT agent was added for 3 h. N-terminal repressor form Gli3 was determined by
quantifying ECL signal from Western blot and corrected for b-actin (n ¼ 3). Depicted is the mean 6 SEM.
(C) Gli specificity of the inhibitory effect of 10 lM vitamin D3 was assayed by using a panel of luciferase reporter constructs, one of which was a mGli
reporter (mGli-LUC). Cells were stimulated for 6 h with vitamin D3, and the luciferase activity was assayed; values were calculated from RLU values
corrected for an internal CMV Renilla standard and expressed as percent difference to control stimulated cells (n   4). Depicted is the mean 6 SEM.
(D) Different cell types share the inhibitory response to vitamin D3 on Gli activity. C3H/10T1/2 and MDA-MD-231 cells were used earlier in the mix-and-
match and medium transfer experiments. Ptch1
–/– MEFs served as a control for any possible effects of vitamin D3 on Ptch1 function. Cells were
stimulated for 6 h, and the luciferase activity was assayed,; values are RLU values corrected for an internal CMV Renilla standard and expressed as
percent difference to control stimulated cells (n ¼ 4). Depicted is the mean 6 SEM.
(E) Proposed mechanism of vitamin D3 action. First panel: in the presence of Hh, Ptch1 is inactive and does not inhibit Smo. The Hh pathway is active,
and Gli activity can be measured in a reporter assay. Second panel: in the absence of Hh, Ptch1 is active and uses vitamin D3 to inhibit Smo. The
pathway is inactive, and low Gli activity is measured. Third panel: in the presence of Hh as well as exogenous D3, Smo is inhibited independently of
Ptch1, and Hh can no longer elicit a Gli response.
(F) Confluent Shh-LIGHT II stable Gli reporter transfectants were stimulated with 10 lM vitamin D3 and/or 200 ng/ml Shh overnight in the presence of
0.5% FCS. Luciferase activity was assayed; values are RLU values corrected for an internal CMV Renilla standard and expressed as percent difference to
control stimulated cells (0 lM vitamin D3; 0 ng/ml Shh). In the presence of vitamin D3, Shh is no longer able to induce reporter activity. n¼4; depicted
is the mean 6 SEM.
DOI: 10.1371/journal.pbio.0040232.g006
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Repression of Smoothened by Patchedas cyclopamine, indicating that vitamin D3 is indeed a
physiological ligand for Smo.
Vitamin D3 Treatment Mimics the smo
–/– Phenotype in
Zebrafish
To test the action of vitamin D3 in a developmental in vivo
model system, we continuously incubated zebraﬁsh embryos
starting between 32- and 64-cell stage in 1.2 mg/ml sonicated
vitamin D3. We used sonication as described for 7-DHC [29],
but did not use a stabilizing reagent. The vitamin D3
treatment phenocopied to a great extent the slow muscle
omitted (smu) mutant phenotype [30], which has been identiﬁed
as the zebraﬁsh ortholog of smo [31,32].
One of the most striking features of the smo
–/– phenotype is
the U-shaped somites in contrast to the sharply deﬁned
chevron (V)-shaped somites of wild-type embryos. The
vitamin D3–treated embryos showed these disrupted somites
(as indicated by arrow 1 in Figure 8A) at the developmental
stages shown. Of the treated animals, approximately 75% (n¼
30 embryos in six individual experiments) showed this somite
phenotype as well as the typical responses as listed below.
Quantiﬁcation of the somite angle was performed, measuring
the angle between the dorsal and ventral portions of the
individual somites while positioning the apex of the angle on
the horizontal myoseptum (Figure 8B, top panel). In properly
shaped somites, this angle was relatively sharp, whereas in
vitamin D3–treated embryos, somites were kidney-shaped,
displaying a shallow angle (Figure 8B). The ventrally curved
body that is characteristic of smo
–/– zebraﬁsh embryos was also
observed upon vitamin D3 treatment. The horizontal
myoseptum was malformed (Figure 8A; see also Figure 1B
of [32]). Another aspect of the smo
–/– phenotype is the
aberrant extension of the yolk tube, resulting in a shorter
and thicker yolk tube; this was also clearly noticeable in the
vitamin D3–treated embryos (indicated by arrow 2 in Figure
8A; compare to Figure 1A of [32] and Figure 4 of [31]).
Although motoneurons have been described to be missing in
smo
–/– animals [32], we observed no apparent difference in
touch response between control and vitamin D3 animals. To
our knowledge not previously reported, it appeared that the
dorsal midbrain was more prominent in the treated embryos
versus controls, resembling the prominent dorsal midbrain in
smo
–/– embryos (indicated by arrow 3 in Figure 8A; compare to
Figure 1 of [32] and Figure 4 of [31]). Also, note the similarity
of the treated embryo shown at 18 h with regard to a reduced
trunk, possibly caused by increased cell death as shown for
smo mutants (indicated by arrow 4 in Figure 8A; compare to
Figure 8B of [33]).
To assess the speciﬁcity of vitamin D3 action on the Hh
pathway, we used molecular markers speciﬁc for Hh pathway
activity in zebraﬁsh. The protein Engrailed is a marker for
muscle pioneers in normal development, and as development
advances, it is also expressed in the cells surrounding the
muscle pioneers [34]. In zebraﬁsh embryos with an abrogated
Hh signalling, muscle pioneers fail to differentiate and
Engrailed is totally absent [31,35–37]. No Engrailed staining
of muscle pioneers (indicated by arrow in Figure 8, panel
labelled 4D9) or surrounding cells was observed in vitamin
D3–treated embryos, suggestive of inhibition of Hh signalling
by vitamin D3. In the control-treated animals, staining of
muscle pioneers as well as ventrally located cells in the
somites was observed. Expression of ptc1 as determined by in
situ hybridisation (ISH) (Figure 8A, ptc1) showed a marked
reduction of transcript levels in the vitamin D3–treated
animals. Because ptc1 is not only the primary receptor for the
Hh pathway but also a transcriptional readout of Hh activity
[32,37], the attenuated expression seen in the treated animals
conﬁrms that vitamin D3 speciﬁcally inhibits the Hh pathway.
Another marker previously described to be indicative of Hh
pathway activity is slow muscle ﬁbre orientation and number
in the somites. In smo
–/– zebraﬁsh, slow muscle ﬁbres are fewer
and malformed [30,31]. Shown in Figure 8 (panel marked F59)
is the disturbed pattern and number of slow muscle ﬁbres
after vitamin D3 treatment, reminiscent of smo
–/– zebraﬁsh
embryos. The use of the abovementioned molecular markers
conﬁrms that the effects of vitamin D3 on zebraﬁsh embryo
morphology are indeed due to reduced Hh pathway activity.
At later stages, we observed a subtle cardiac edema, and all
treated embryos died after 5 d of vitamin D3 treatment, a
feature again similar to the smo
–/– phenotype (Figure 8C).
Although we found the eyes to be relatively ventrally
positioned throughout various developmental stages (Figure
8C), no absolute cyclopia was observed. However, cyclopia is
not an unambiguous hallmark of the smo-deﬁcient phenotype
[31–33].
Because nearly all of the typical smo
–/– phenotypic features
were also prominently present in vitamin D3–treated zebra-
ﬁsh embryos and the molecular markers used all pointed to a
defective Hh signalling, we conclude that the in vivo action of
Figure 7. Scatchard Analysis of Vitamin D3 Using Smo-Expressing P.
pastoris
(A) 24 h methanol induction (buffered methanol-complex medium;
BMMY) of Smo-transformed P. pastoris yielded successful Smo expression
as shown by Western blot analysis with an antibody directed against
Smo.
(B) Scatchard analysis of heterologous competition with cyclopamine
representing the binding of [3H]-D3 to Smo-expressing (solid circles,
MeOH induced) and nonexpressing (open circles, noninduced) yeast
strains. The solid line indicates the induced high-affinity binding,
whereas the dotted line indicates nonspecific low-affinity binding.
Scatchard analysis and fitting was performed as described earlier [53].
DOI: 10.1371/journal.pbio.0040232.g007
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inhibitory effect on Smo.
Discussion
In the present study, we investigated the molecular mode
by which Ptch1 represses Smo activity. By mixing Ptch1-
expressing cells with cells expressing Smo and a Gli reporter,
we were able to show that Ptch1 is capable of non–cell
autonomous repression of Smo. This non–cell autonomous
repression is carried by the extracellular medium, because
medium conditioned by Ptch1-transfected cells was capable
of inhibiting Gli reporter activity as well. Conversely, medium
conditioned by cells transfected with Ptch1 siRNA (so lacking
endogenous Ptch1 expression) elevated Gli reporter activity
signiﬁcantly above medium that was conditioned by control
cells, demonstrating that Ptch1 overexpression is not a
prerequisite for observing this cell non-autonomous repres-
sion of Smo by Ptch1. Mixing Ptch1-overexpression cells with
cells expressing Smo and Gli reporter produced inhibition of
Gli reporter activity to approximately the same extent as
fusing these cells, showing that this non–cell autonomous
Figure 8. Effects of Vitamin D3 on Developing Zebrafish Embryos
(A) Fertilized zebrafish eggs were dechorionated and placed in buffer containing 1.2 mg/ml sonicated vitamin D3, starting the continuous incubation
between the 32- and 64-cell stages. At the different developmental stages (as indicated), the embryos were analysed, revealing persistent somite
malformations, a ventrally curved body, poorly developed myoseptum, an aberrant extension of the yolk tube, a prominent dorsal midbrain, and a
reduced trunk. The wild-type Engrailed staining (4D9) of muscle pioneers and surrounding cells in control-treated animals was not observed upon
vitamin D3 treatment. ISH for ptc1 mRNA showed a strongly reduced signal in vitamin D3–treated animals compared with controls. Staining with the
F59 antibody revealed that slow muscle fibres were disturbed in number and orientation in the treated animals.
(B) At 18 hpf, embryos were photographed in detail and somite angles were determined (as shown in top panel). The measurement was taken of an
individual somite between dorsal and ventral portions of the vertical myoseptum for corresponding somites between the wild-type and vitamin D3–
treated embryos. Shown are the mean angles (6SEM; n ¼ 3) of wild-type control- and vitamin D3–treated embryos.
C) Detail of 4-dpf embryo. Note the slightly enlarged pericardial cavity in vitamin D3–treated animals. The orientation of all images is a lateral view,
anterior to the left.
DOI: 10.1371/journal.pbio.0040232.g008
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compared to intracellular Smo repression by Ptch1. This
result suggests that this intercellular repression constitutes an
important physiological mechanism. In this context, it is
important to note that Hh quenching was not a major
contributing factor in our experimental system, because Hh-
neutralising antibodies do not interfere with Ptch1-depend-
ent intercellular repression of Smo and we were not able to
detect Hh release by the cells.
Conditioning medium with Ptch1-transfected cells led to
the appearance of a 3b-hydroxysteroid in this medium,
suggesting that this compound is increasingly translocated
into the medium as a consequence of elevated Ptch1
expression. These results are concordant with the observation
that Smo antagonists bear structural similarities to steroids
[12] and the high homology of Ptch1 to the NPC1 protein,
which has cholesterol trafﬁcking and pump functions [10], as
well as to various prokaryotic pump proteins. These homol-
ogies gave rise to the suggestion that, in the absence of Hh,
Ptch1 pumps a compound out of the cell that binds to and
inhibits Smo, and the data from this study conﬁrm this model.
Transfection of Ptch1 siRNA abolished deposition of this 3b-
hydroxysteroid into the medium when compared to control-
transfected cells, showing that 3b-hydroxysteroid transloca-
tion is not an artefact of Ptch1 overexpression, but that
endogenous Ptch1 expression levels are sufﬁcient to sustain
detectable 3b-hydroxysteroid translocation. This 3b-hydrox-
ysteroid translocation seems important for the intercellular
repression of Smo by Ptch1, because in the presence of 3b-
hydroxysteroid synthesis inhibitors Ptch1 was no longer
capable of repressing Smo, whereas artiﬁcial stimulation of
3b-hydroxysteroid biosynthesis by using mevalonate supple-
mentation enhanced theinhibitory potential of Ptch1 onSmo.
The 3b-hydroxysteroid responsible for intercellular repres-
sion of Smo is most likely the (pro-)vitamin D3 (that is, either
7-DHC or its metabolite vitamin D3) or a highly similar
molecule. Fibroblasts derived from animals genetically
incapable of synthesizing these 3b-hydroxysteroids (Sc5d
–/–)
do not sustain intercellular repression of Smo by Ptch1,
whereas ﬁbroblasts that have a genetic defect leading to
increased (pro-)vitamin D3 production (Dhcr7
–/–) show ex-
aggerated intercellular repression of Smo by Ptch1. Exoge-
nous addition of vitamin D3 was more efﬁcient in inhibiting
Gli reporter activity than the established Smo antagonist
cyclopamine. SmoM2, which has a reduced sensitivity towards
cyclopamine, showed diminished sensitivity to vitamin D3 as
well. In Scatchard assays, cyclopamine and vitamin D3
competed for Smo binding, suggesting that both compounds
have an identical binding site on Smo. Scatchard analysis
using the precursor 7-DHC as a competitor revealed a 10-fold
l o w e ra f ﬁ n i t yf o rS m ot h a nd i dv i t a m i nD 3o rt h e
hydroxylated (active) form of vitamin D3 (unpublished data).
Treatment of Danio rerio embryos with vitamin D3 phenocop-
ied most of the aspects of the smo
–/– phenotype in zebraﬁsh.
These ﬁndings strongly suggest that Ptch1 translocates either
vitamin D3, a related molecule, or possibly a precursor that is
subsequently metabolised in the extracellular medium that
acts as a Smo antagonist.
Our ﬁndings shed light on the puzzling biochemical basis of
SLOS, in which accumulation of 7-DHC (Figure 1A)
accompanies a reduced cholesterol content and a seemingly
decreased Hh signalling [38]. Previously, the SLOS phenotype
has been mimicked by using AY-9944 [25], which inhibits 7-
DHC reductase (Figure 1A), leading to the accumulation of its
substrate. This result suggests that this molecule mediates Hh
inhibition. Treatment of patients with a cholesterol-rich diet,
however, has been successful, and statin treatment does not
seem to alleviate the symptoms, suggesting that the lack of
cholesterol is the culprit [38,39]. Others have been able to
counteract the effect of 7-DHC stacking in experimental
settings by exogenously adding cholesterol [40], conﬁrming
that AY-9944 merely inhibits synthesis of cholesterol needed
for proper Hh processing. Although these ﬁndings seem to
preclude the stacking of a speciﬁc metabolite to be
responsible for the SLOS phenotype, it has become clear
that the clinical phenotype correlates best with the ratio of 7-
DHC to cholesterol levels in patient plasma rather than the
levels of cholesterol alone. Also, the treatment of infants with
cholesterol is arguably too late an intervention, because most
of the Hh patterning events are completed in utero. Our
experiments show that even in the absence of AY-9944,
addition of vitamin D3 strongly inhibits Hh signalling. This
inhibition is stronger than Ptch1 cotransfection and Ptch1-
transfectant conditioned medium, and we therefore conclude
that the stacking of 7-DHC is responsible for the SLOS
phenotype.
Very relevant to this manuscript and the abovementioned
studies are the ﬁndings of Cooper et al., who found that
reduced sterol levels impair a cell’s responsiveness to Hh [8].
By using ﬁbroblasts from mice genetically deﬁcient for the
enzymes involved in lathosterolosis (Sc5d) and SLOS (Dhcr7)
and by depleting lipids and sterols from the medium, they
showed that sterol levels were crucial to a cell’s responsive-
ness to Hh. By analyzing the Hh protein in these cells under
the various conditions, they could demonstrate proper Hh
maturation, thereby excluding improper Hh sterolation as
the cause of SLOS. They did not, however, hypothesize an
inhibitory role for excess cholesterol precursors. We explain
our hypothesis and ﬁndings in light of their results: by genetic
and/or medium condition causes, steroid synthesis is seriously
impaired in cells in their experiments. As a result, 7-DHC
levels will drop, leaving Ptch1 devoid of substrate. Without
substrate to pump or translocate, Ptch1 is ‘‘paralysed’’, and
addition of Hh will not exert an effect, explaining the
reduced responsiveness. Hh responsiveness does not equal
pathway activity, and the absence of Ptch1 substrate will
diminish responsiveness but not pathway activity. Because
both cell lines share the inability to properly synthesize
cholesterol, and because we ﬁnd a differential inhibitory
potential on Smo, we conclude that sterol content alone
cannot account for Ptch1-mediated Smo inhibition, and we
suggest that the effects found by other groups take place
elsewhere in the Hh signalling pathway. In our system, LDL
seems to be a prerequisite for the diffusion of the inhibitory
molecule, and, recently, a similar requirement has also been
found for the distribution of Hh itself [41].
Although the present study clearly demonstrates that Ptch1
can inhibit Smo in an intercellular fashion, we have not
addressed whether such intercellular action of Ptch1 on Smo
is relevant for Hh action in vivo. Vitamin D3 is highly
hydrophobic and is not expected to diffuse very far in the
aqueous environment that surrounds cells. We observed that
in the absence of LDL as a carrier for the hydrophobic Smo
inhibitor, intercellular repression of Smo activity was
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D3, it might act on Smo on the same cell (and thus function
cell autonomously) or, depending on the cell’s surroundings,
on Smo on adjacent cells (and thus function non–cell
autonomously). Nevertheless, the expression of Ptch1 and
Smo is often discordant, with Ptch1 expression being in the
vicinity of Smo-expressing cells, without complete colocalisa-
tion [42,43]. We observed that in cardiac nerve branch
ganglia, Smo and Ptch1 colocalise in the bronchial cartilage
and epithelium, but not in the ganglion itself. In the ganglion,
a pronounced staining for Ptch1 can be seen, whereas Smo
staining is observed in only the adjacent cells. These ﬁndings
are suggestive for intercellular signalling actually occurring in
vivo (MF Bijlsma, unpublished data). In contrast with these
ﬁndings are earlier reported experiments by Briscoe et al.
[44] in which a Hh uninhabitable form of Ptch1 (Ptch1
Dloop2)
was evaluated with respect to its effects on Hh signalling in
Drosophila melanogaster and Gallus gallus embryogenesis. The
results obtained in this study suggest that the border of
Ptch1
Dloop2 expression more or less corresponds with the
boundary of Hh-induced gene expression. Thus, it would
appear that in these experimental systems, a Smo-inhibitory,
vitamin D3–like ligand has not much capacity to diffuse over
multiple cell layers. We therefore suggest that the action of
Ptch1 can be cell autonomous or non–cell autonomous in
various in vivo situations, perhaps dependent on the presence
or absence of molecules that can carry the hydrophobic
ligand over larger distances and subsequently present this
molecule to Smo.
Recently it was demonstrated that Hh-bound Ptch1 could
titrate the inhibitory action of the abovementioned
Ptch1
Dloop2. Furthermore, Hh-bound Ptch1 allowed Smo
signalling to occur even in the presence of a Ptch1 form that
is incapable of binding Hh [45]. This observation is incon-
sistent with a model in which Ptch1 serves to translocate a
Smo-inhibitory molecule out of the cell, because in this
model, Ptch1 action would depend on the amount of
unliganded Ptch1, not the amount of liganded Ptch1. Casali
and Struhl provide as a possible explanation for the titration
effect that liganded and unliganded Ptch1 compete for access
to Smo: Ptch1 acts as a multimer in which binding of Hh to
any of the subunits blocks the action of the complex, or
liganded and unliganded Ptch1 exert counteracting catalytic
activities. Only the latter explanation seems consistent with
the data presented in this study; the other explanation
requires Ptch1 to function in a cell-autonomous fashion.
Hence, it is possible that unliganded Ptch1 translocates a Smo
inhibitor to extracellular medium, whereas Hh-bound Ptch1
would transport this inhibitor to the cytosol. Alternatively,
Hh-bound Ptch1 is internalized, and it is possible that in this
process it cointernalizes the Ptch1
Dloop2 protein, especially if
both proteins would localize to the same plasma membrane
compartment—for example, lipid rafts. Support for this
notion might be deduced from the strong Hh-dependent
endocytosis we observed in the present study, suggesting that
endocytosis is indeed a major cellular response to Hh binding
to Ptch1. But further studies are needed to address the exact
mode by which wild-type Ptch1 impairs Ptch1
Dloop2 function.
Activation of the Hh pathway is, under certain conditions,
associated with the development of cancer, especially in the
upper digestive tract [46,47] and in basal cell carcinoma in the
skin, where this disease is linked to mutations in Ptch1 [48–51].
Intercellular action of Ptch1 will allow this molecule to exert
its action as a tumour suppressor, on not only the Ptch1-
expressing cell but also neighbouring cells that may have
acquired inactivating mutations of Ptch1, making this mode of
Ptch1-dependent Smo inhibition especially attractive with
respect to tumour suppression. Thus, it will be interesting to
investigate whether intercellular repression of Smo by Ptch1
actually contributes to tumour suppression in vivo. Experi-
ments addressing this possibility are currently in progress.
Materials and Methods
Constructs/siRNA used. Mouse Ptch1 (a generous gift of Dr. M. P.
Scott) was cloned into the pcDNA 3.1(–) vector (Invitrogen, Carlsbad,
California, United States). Human SMO (referred to as Smo) cDNA
(Image Consortium/RZPD, Berlin, Germany) was cloned into the
pcDNA 3.1(þ) vector. The Gli1 cDNA is in pcDNA1 (a generous gift of
Dr. A. Ruiz i Altaba). The Gli-reporter d51-LucII was kindly provided
by Dr. H. Sasaki, as was the mutant binding site variant (mGli). The
NF-jB, ISRE, and TAL luciferase constructs were from Clontech
Laboratories (Mountain View, California, United States). The internal
control cytomegalovirus (CMV) promoter-driven Renilla luciferase
vector was from Promega (Madison, Wisconsin, United States).
SmoM2 in pRK7 was obtained from Genentech (South San Francisco,
California, United States). The Ptch1 (#63908) and scrambled control
siRNA were from Ambion (Austin, Texas, United States).
Western blotting. Transfected cells were lysed in Laemmli buffer
and brought onto SDS-PAGE gels. After electrophoresis, protein was
transferred onto Immobilon-PVDF membranes (Millipore, Billerica,
Massachusetts, United States). Membranes were blocked in 5% bovine
serum albumin (BSA) (Sigma-Aldrich, St Louis, Missouri, United
States) in TBS/0.1% Tween-20 (TBST) for 1 h. Goat polyclonal a-
Ptch1 antibody G-19, a-Smo C-17, a-Gli3 N-terminal N-19, a-Shh N-
19, or a-Ihh I-19 (Santa Cruz Biotechnology, Santa Cruz, California,
United States) were diluted to 1:500 in 3% BSA in TBST, and
membranes were incubated overnight. Goat polyclonal a-actin I-19
(Santa Cruz Biotechnology) was diluted to 1:1000 in 3% BSA in TBST.
After 1 h incubation in 1:1000 a-goat HRP-conjugated secondary
antibody (DakoCytomation, Glostrup, Denmark), blots were imaged
using LumiLight Plus enhanced chemiluminescence substrate (ECL)
(Roche, Basel, Switzerland) on a GeneGnome chemiluminescence
imager (Syngene, Cambridge, United Kingdom).
Mix-and-match procedure. Mouse mesenchymal ﬁbroblasts (C3H/
10T1/2 from American Type Culture Collection CCL-226, Manassas,
Virginia, United States) were grown in Dulbecco’s Modiﬁed Eagle
Medium (DMEM) (Cambrex, East Rutherford, New Jersey, United
States) containing 10% fetal calf serum (FCS) (Cambrex). Human
MDA-MB-231 breast carcinoma cells (American Type Culture
Collection HTB-26) were grown in L-15 Leibovitz medium (Cambrex)
with 10% FCS. Cells were grown to approximately 70% and
transfected with either Ptch1 or Smo and the Gli luciferase reporter
in combination with a CMV-Renilla luciferase internal standard using
Effectene (Qiagen, Hilden, Germany) according to routine proce-
dures. Ptch1 and scrambled control siRNA were transfected using
RNAiFect (Qiagen) following the supplied protocol. Transfected cells
were treated with o-methylated 20 lM zVADfmk (Sigma-Aldrich) to
neutralize the apoptotic effects of Ptch1. After 16 h, cells were washed
three times with phosphate buffered saline (PBS), detached by 2 mM
EDTA (Sigma-Aldrich) in PBS, resuspended in DMEM with 10% FCS,
and pipetted three times through a 40-lm cell strainer (BD
Biosciences, San Jose, California, United States) into a tube to allow
a homogenous mixture. Equal volumes of reporter and donor cells
were mixed thoroughly and subsequently transferred to 24-well
plates. After 6 h (4þ2 h for the fusion protocol), cells were lysed with
passive lysis buffer as provided by Promega, and luciferase activity
was assayed according to the Promega Dual-Glo Luciferase Assay
System (Promega) protocol on a Lumat Berthold LB 9501 Lumin-
ometer (Berthold Technologies, Bad Wildbad, Germany). Each ﬁreﬂy
luciferase value was corrected for its cotransfected CMV-driven
Renilla luciferase standard to correct for transfection efﬁciency or
dilution effects. Recombinant N-terminal Shh was obtained from
R&D Systems (Minneapolis, Minnesota, United States) and dissolved
in PBS with 0.1% BSA. The 5E1 Shh-blocking antibody was from the
Developmental Hybridoma Bank (Iowa City, Iowa, United States).
Fluorescent tracking of cells. Cells were grown to approximately
70% conﬂuence in DMEM containing 10% FCS and washed with PBS
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(Molecular Probes, Eugene, Oregon, United States) were diluted to 5
lM in serum-free DMEM and added to cells for 45 min, the medium
was aspirated, and fresh medium containing 10% FCS was added.
Cells were detached and mixed as described above. After 16 h, cells
were ﬁxed in 3.7% formaldehyde overnight or mixed as described
above and subsequently ﬁxed. For ﬂuorescent staining of nuclei, cells
were washed with PBS/0.1% Triton X-100 (PBST) and incubated in
200 ng/ml DAPI (Roche) in PBST for 1 h. Before microscopy, cells on
cover slips were washed brieﬂy in PBS, placed upside-down on
another cover slip if imaged on a Leica TCS SP II confocal laser
scanning microscope (Leica Microsystems, Wetzlar, Germany), or
placed on an object glass when imaged on a Zeiss Axioskop (Carl
Zeiss, Oberkochen, Germany).
Cell fusion. After ﬂuorescent labelling (1 h) or transfection (16 h),
cells were mixed, medium was aspirated, and cells were washed with
PBS. Prewarmed PEG 1500/HEPES (pH 7.4) 50% (Roche) was added
to the cells for 90 s, after which the cells were washed three times with
PBS. Fresh medium was added, and after 2 h, cells were either lysed
with passive lysis buffer and assayed for luciferase activity or ﬁxed for
microscopy after 8 h.
Medium transfer experiments. Donor and reporter cells were
transfected for 16 h, after which the donor cells were washed
extensively to wash out any remaining transfection complexes and
supplied with fresh medium for 6 h. Medium was transferred to
reporter cells for 6 to 8 h, after which cells were lysed and assayed for
luciferase activity (according to manufacturer’s protocol). The
mutant MEFs were grown in complete DMEM supplemented with
15% FCS and nonessential amino acids (Sigma).
CHOD-PAP–coupled FPLC. Steroid levels in the main lipoprotein
classes (VLDL, LDL, and HDL) were determined using high-perform-
ance gel ﬁltration chromatography. The system contained a PU-980
ternary pump with an LG-980–02 linear degasser, FP-920 ﬂuores-
cence, and UV-975 UV/VIS detectors (Jasco, Tokyo, Japan). An extra
P-50 pump (Pharmacia Biotech, Uppsala, Sweden) was used for in-
line CHOD-PAP enzymatic reagent (Biomerieux, Marcy l’Etoile,
France) addition at 0.1 ml/min. 60 ll from each sample was subjected
to size-exclusion chromatography to determine whether there is a
relationship between Ptch1 expression and medium 3b-hydroxyste-
roid levels using a Superose 6 HR 10/30 (Pharmacia Biotech) column
with Tris-buffered saline (TBS) (pH 7.4) at a ﬂow rate of 0.31 ml/min
with in-line ﬂuorescence and UV detection on the Jasco system with
CHOD-PAP assay described above. Commercially available lipid
plasma standards were used for total cholesterol pattern analysis
(SKZL, Nijmegen, Netherlands).
Endocytosis assay. Cells on 24-well plates were grown to 70%
conﬂuence and treated with no or 1 mM pravastatin for 6 h.
Subsequently, 200 nCi of [3H]-labelled sucrose (Amersham Pharmacia
Biotech, Freiburg, Germany) was added per well. Cells were
stimulated with either 1 lg/ml Shh or solvent control (0.1% BSA/
PBS) for 1 h. After washing, cells were lysed in 1% Nonidet P-40 and
the lysate was transferred to 4 ml of scintillation ﬂuid and activity was
determined on a Packard Tri-Carb scintillation counter (PerkinElm-
er, Wellesley, Massachusetts, United States). Values were corrected for
solvent control treated cells on ice.
Stimulation experiments. Cells transfected with the Gli-luciferase
reporter were stimulated for the indicated times and concentrations
with the following: cyclopamine (Biomol, Plymouth Meeting, Penn-
sylvania, United States), AY-9944 (Calbiochem, San Diego, California,
United States), vitamin D3, or 7-DHC (Sigma).
MTT assay. Cells were seeded in ﬂat-bottom 96-well plates and
treated with the indicated concentrations of vitamin D3 for 6 h.
During the last 3 h, 0.5 mg/ml thiazolyl blue tetrazolium bromide
(MTT) was added. After incubation, supernatant was discarded, cells
were lysed in 50 ll of 40 mM HCl in isopropanol, and absorbance was
measured at 570 nm in a Benchmark Plus Microplate Spectropho-
tometer (Bio-Rad, Hercules, California, United States).
P. pastoris culture. The Smo-transformed P. pastoris strain was a
kind gift from Dr. I. Mus-Veteau. Culture of yeast and induction of
Smo expression was performed as described [27].
Scatchard analysis. Scatchard analysis was performed on intact
cells as described earlier for [52,53]. After 24 h growth in methanol-
or glycerol-complex medium, P. pastoris strains were washed with PBS
and diluted to the same OD600. Subsequently, aliquots of cells were
labelled for 1.5 h at 4 8C in PBS containing 1.66 nM of [3H]-labelled
vitamin D3 (Amersham Pharmacia Biotech) and eight different
concentrations of unlabelled cyclopamine, 7-DHC, vitamin D3, or
hydroxylated vitamin D3 (Sigma-Aldrich). The reaction was stopped
by washing four times with ice-cold PBS. The bound radioactivity was
determined by transferring the washed pellets to 4 ml of scintillation
ﬂuid, and activity was determined on a Packard Tri-Carb scintillation
counter (PerkinElmer). In each experiment, each condition was
performed in duplicate. In general, Scatchard plots on intact cells
show considerable nonspeciﬁc low-afﬁnity binding of [3H]-vitamin
D3. Therefore, Scatchard plots were ﬁtted according to a one- or two-
site model, as appropriate. The observed points of noninduced yeast
were a satisfactory ﬁt with a one-site (low afﬁnity) model, whereas two
afﬁnity sites could be distinguished in the induced P. pastoris.
Animals. Wild-type zebraﬁsh (D. rerio) were kept and bred
according to standard protocols. 1- to 1.5-h post fertilisation (hpf)
embryos were dechorionated following 2 mg/ml pronase treatment
for 1 min followed by extensive rinsing. 1.2 mg/ml vitamin D3 was
added to HEPES buffered Ringer’s solution and sonicated on ice for 3
min; control buffer was also sonicated. Suspension temperatures were
equilibrated and added to the embryos.
ISH and immunoﬂuorescence. After treatment, embryos were ﬁxed
in 4% paraformaldehyde/PBS, and ISH was carried out as described
[54] using a ptc1 probe synthesized according to [55]. The 4D9 and F59
antibodies were obtained from the Developmental Hybridoma Bank
and used as previously described [56].
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